within Pharmacolibrary.Drugs.ATC.L;

model L03AB12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0005666666666666667,
    adminDuration  = 600,
    adminMass      = 0.9,
    adminCount     = 1,
    Vd             = 0.005900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Albinterferon alfa-2b is a recombinant fusion protein of human albumin and interferon alfa-2b developed as a long-acting form of interferon for the treatment of chronic hepatitis C infection. It was intended to offer less frequent dosing schedules compared to traditional pegylated interferons, but its development was discontinued and it is not approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult subjects and patients with chronic hepatitis C, reported after subcutaneous administration.</p><h4>References</h4><ol><li>Matthew M Riggs, Timothy T Bergsma, James A Rogers, Marc R Gastonguay, G Mani Subramanian, Cecil Chen, Matt Devalaraja, Alfred E Corey, Haiying Sun, Jing Yu, Daniel S Stein,Population pharmacokinetics and exposure-response of albinterferon alfa-2b.,Journal of clinical pharmacology,2012<a href='https://pubmed.ncbi.nlm.nih.gov/21551316/'>https://pubmed.ncbi.nlm.nih.gov/21551316/</a></li><li>Vinod K Rustgi,Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.,Current medical research and opinion,2009<a href='https://pubmed.ncbi.nlm.nih.gov/19275518/'>https://pubmed.ncbi.nlm.nih.gov/19275518/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB12;
